Healthcare Industry News:  Aggrastat 

Devices Cardiology

 News Release - September 12, 2006

Heartscape Technologies Appoints Arthur Hiller, former Millennium Head of Cardiovascular Business, as CEO and Director

COLUMBIA, Md.--(HSMN NewsFeed)--Sept. 12, 2006--Heartscape Technologies, Inc. ("Heartscape" or the "Company"), a cardiology device company focused on the earliest diagnosis and fastest treatment of heart attacks, announced that it has appointed Arthur Hiller, former SVP at Millennium Pharmaceuticals, Inc. ("Millennium"), as CEO and Director. Founder Carl Rebert remains with Heartscape as President, COO and Director.

Hiller brings to Heartscape a strong track record in cardiovascular marketing, sales, and business development. At Millennium, he headed up the cardiovascular business following the acquisition of Cor Therapeutics in 2002. He successfully led the product re-branding and re-positioning of INTEGRILIN®, a glycoprotein IIb-IIIa inhibitor agent for the treatment of patients with acute coronary syndromes, including unstable angina and evolving myocardial infarctions, or heart attacks. Prior to joining Millennium, Hiller was Vice President, Worldwide Human Health Marketing for Hospital Products at Merck, where he led the international launch of Aggrastat®, another product for use in acute cardiovascular care.

"Arthur brings highly relevant experience from Millennium and Merck in the cardiovascular and emergency room arena. He has the ideal background to position the PRIME ECG®("PRIME") System in these distinct but related medical specialties and is a great addition to the Heartscape management team and board," said Jordan Davis, Managing Partner of Radius Ventures and Chairman of Heartscape Technologies, as he welcomed Hiller's appointment.

"PRIME is an exciting technology that can help save lives and improve outcomes for potentially hundreds of thousands of heart attack victims annually," said Hiller. "Improving diagnosis and care of heart attack patients is broadly acknowledged by hospitals, physicians, and payers to be one of the most critical and most challenging areas in cardiology today. Heartscape has already assembled a solid base of published clinical evidence that has resulted in both FDA clearance and early sales success for PRIME. I am looking forward to the opportunity of broadly educating hospitals, physicians and payers on the potential for PRIME to enhance the quality of patient care and lower overall health-related costs."

"In the management of heart attack victims, time is muscle and rapid diagnosis can be the difference between life and death and clearly impacts a patient's long-term prognosis. The potential exists for PRIME to identify many more patients suffering from heart attacks than traditional ECG technology, even prior to the emergence of positive cardiovascular biomarkers in the blood. The new insight provided by PRIME offers the potential for more high-risk patients to be aggressively treated by cardiologists within one hour to 90 minutes of their arrival in the emergency department (in accordance with ACC/AHA Guidelines)," said Joey Mason of Delta Partners."

About Heartscape Technologies, Inc.

Heartscape is engaged in the development and marketing of the PRIME ELECTROCARTOGRAPHY® System, an FDA-cleared medical device that accurately and rapidly diagnoses heart attacks and ischemia in the emergency department setting - enabling earlier intervention, a central factor in reducing patient death and morbidity. Heartscape currently has sales and operations offices located in Columbia, Maryland, and R & D and manufacturing facilities in Bangor, Northern Ireland. Developed in collaboration with the University of Ulster in Northern Ireland, the PRIME technology provides the hospital acute cardiac care team with an 80-electrode, 360-degree view of the heart's electrical activity to more accurately identify abnormal signals that may indicate a heart attack in areas not visible to the current 12-electrode standard electrocardiogram (ECG). The PRIME system consists of a rapidly administered, single-use, disposable plastic vest that connects to a compact, mobile computer workstation allowing users to view the heart's electrical activity using multiple display options that offer traditional ECG tracings or easily-interpreted 3D graphics.

About Radius Ventures

Radius Ventures is a venture capital firm focused primarily on early-stage opportunities in the health and life sciences industry. Radius currently manages two funds with total committed capital of approximately $100 million.

About Delta Partners

Delta Partners is a venture capital firm established in Ireland in 1994 focusing on early stage seed and start up businesses. With over $150 million under management, the team has made over 50 investments in the following sectors: Communications, Internet, Software and Life Sciences.

PRIME ECG and ELECTROCARTOGRAPHY are registered trademarks of Heartscape Technologies, Inc.

INTEGRILIN is a registered trademark of Millennium Pharmaceuticals, Inc.

Aggrastat is a registered trademark of Guilford Pharmaceuticals, Inc.

Source: Heartscape Technologies

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.